Smith & Nephew/£SN

07:00
15:10
23:15
07:25
15:30
1D1W1MYTD1Y5YMAX

About Smith & Nephew

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Ticker

£SN
Sector

Primary listing

LSE

Employees

17,000

Smith & Nephew Metrics

BasicAdvanced
£11B
31.65
£0.42
0.67
£0.29
2.16%

What the Analysts think about Smith & Nephew

Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.

Bulls say / Bears say

Smith & Nephew reaffirmed its full-year 2025 guidance for about 5 percent underlying revenue growth and a 19–20 percent trading profit margin after releasing Q1 results, highlighting management’s confidence in steady performance (Reuters).
The company secured a 10-year contract worth up to $75 million with the U.S. Department of Defense for its RENASYS TOUCH Negative Pressure Wound Therapy systems, strengthening the Advanced Wound Management portfolio and reinforcing product leadership (Reuters).
A $500 million share buyback program was announced for H2 2025, demonstrating strong free cash flow from the 12-Point Plan and a commitment to shareholder returns (Reuters).
US tariffs are expected to impose a net $15–20 million headwind on full-year 2025 results, which could squeeze trading profit margins despite solid underlying growth goals (Reuters).
Emerging Markets revenue slipped by 0.2 percent in Q2 2025, highlighting ongoing weakness in China even as other regions posted stronger gains (Smith & Nephew).
Margins in the Sports Medicine & ENT segment contracted by 130 basis points in H1 2025 due to headwinds from China’s Volume-Based Procurement (VBP), with a further ~$25 million revenue hit anticipated in H2 (Smith & Nephew).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

Smith & Nephew Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Smith & Nephew Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £SN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

FAQs